10 completed, 2 recruiting, 2 terminated, 1 unknown. 16 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 10, Recruiting 2, Terminated 2, Unknown 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow Glomerulosclerosis, Focal Segmental: new trials by email Literature Review of Glomerulosclerosis, Focal Segmental trials Research Report on Glomerulosclerosis, Focal Segmental
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment IXP - Focal Segmental Glomerulosclerosis (FSGS) | Phase 1 | Completed | Vertex Pharmaceuticals Incorporated | 36 | 2024-08-02 | 2025-01-20 |
| AMPK-activation by Metformin in FSGS: AMP-FSGS Metformin + Standard of Care, Placebo + Standard of Care - Focal Segmental Glomerulosclerosis | Phase 1 / Phase 2 | Recruiting | Yale University | 30 | 2023-12-14 | 2026-02-03 |
| A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147 VX-147 - Focal Segmental Glomerulosclerosis (FSGS) | Phase 1 | Completed | Vertex Pharmaceuticals Incorporated | 21 | 2023-07-19 | 2023-09-13 |
| A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects HS-10390 tablet, Placebo tablet - IgA Nephropathy, Focal Segmental Glomerulosclerosis | Phase 1 | Recruiting | Hansoh BioMedical R&D Company | 84 | 2023-05-23 | 2024-10-09 |
| Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria ALXN1720 - Proteinuria | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 13 | 2022-06-29 | 2023-06-29 |
| Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension RE-021, sparsentan - Healthy Subjects | Phase 1 | Completed | Travere Therapeutics, Inc. | 47 | 2020-06-18 | 2022-09-30 |
| FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects GFB-887, Placebo - Healthy Volunteers | Phase 1 | Completed | Goldfinch Bio, Inc. | 70 | 2019-05-29 | 2020-06-02 |
| Stem Cell Therapy for Patients With Focal Segmental Glomerulosclerosis Bone marrow stem cell - Focal Segmental Glomerulosclerosis, Chronic Kidney Diseases | Phase 1 | Completed | Universidade Federal do Rio de Janeiro | 5 | 2015-06-25 | 2020-01-28 |
| Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis) Intravenous injection - Focal Segmental Glomerulosclerosis | Phase 1 | Unknown | Royan Institute | 5 | 2015-05-01 | 2015-12-04 |
| Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5 Galactose - Focal Segmental Glomerulosclerosis | Phase 1 | Withdrawn | Northwell Health | 2008-12-01 | 2015-09-07 | |
| Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor Galactose - Focal Segmental Glomerulosclerosis | Phase 1 | Terminated | Northwell Health | 15 | 2008-12-01 | 2015-09-10 |
| Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS) FG-3019 - Focal Segmental Glomerulosclerosis | Phase 1 | Terminated | Kyntra Bio | 2 | 2008-04-01 | 2019-07-31 |
| Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS GC1008 - Focal Segmental Glomerulosclerosis | Phase 1 | Completed | Genzyme, a Sanofi Company | 16 | 2007-05-01 | 2014-03-19 |
| Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS) Rosiglitazone (Avandia), Adalimumab (Humira) - Focal Glomerulosclerosis | Phase 1 | Completed | Northwell Health | 21 | 2005-07-01 | 2007-10-22 |
| Permeability Factor in Focal Segmental Glomerulosclerosis Plasma exchange, Cyclophosphamide - Focal Segmental Glomerulosclerosis | Phase 1 / Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 15 | 2000-12-01 | 2016-02-10 |
| Total Lymphoid Irradiation (TLI) to Prevent Focal Segmental Glomerulosclerosis (FSGS)Recurrence in the Renal Graft Total Lymphoid irradiation - Glomerulosclerosis, Focal | Phase 1 | Completed | University of Sao Paulo | 10 | 2000-01-01 | 2006-07-18 |
Glomerulonephritis, IGA (3) · Proteinuria (3) · Diabetic Nephropathies (2) · Nephrosis, Lipoid (2) · Renal Insufficiency, Chronic (2) · Diabetes Complications (1) · Endocrine System Diseases (1) · Glomerulonephritis (1) · Glomerulonephritis, Membranoproliferative (1) · Hematuria, Benign Familial (1) · Kidney Diseases (1) · Lupus Nephritis (1) · Nephritis (1) · Nephrosis (1)
Female Urogenital Diseases (16) · Female Urogenital Diseases and Pregnancy Complications (16) · Male Urogenital Diseases (16) · Urogenital Diseases (16) · Glomerulonephritis (15) · Kidney Diseases (15) · Nephritis (15) · Urologic Diseases (15) · Pathological Conditions, Signs and Symptoms (5) · Autoimmune Diseases (3) · Disease Attributes (3) · Immune System Diseases (3) · Pathologic Processes (3) · Signs and Symptoms (3) · Urination Disorders (3)
Galactose (2) · Adalimumab (1) · Bone Marrow Purging (1) · Cyclophosphamide (1) · Injections, Intravenous (1) · Metformin (1) · Plasma Exchange (1) · Plasmapheresis (1) · Rosiglitazone (1) · Standard of Care (1) · fresolimumab (1) · pamrevlumab (1) · sparsentan (1)
Northwell Health (3) · Vertex Pharmaceuticals Incorporated (2) · Alexion Pharmaceuticals, Inc. (1) · Genzyme, a Sanofi Company (1) · Goldfinch Bio, Inc. (1) · Hansoh BioMedical R&D Company (1) · Kyntra Bio (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Royan Institute (1) · Travere Therapeutics, Inc. (1) · Universidade Federal do Rio de Janeiro (1) · University of Sao Paulo (1) · Yale University (1)
United States (9) · Brazil (2) · United Kingdom (2) · China (1) · Germany (1) · Iran (1) · Italy (1) · South Korea (1)
Howard Trachtman, MD (3) · Cijiang He (1) · Debbie Gipson, MD (1) · Hamid Gourabi, PhD (1) · Hassan Otukesh, MD (1) · Jeanelle Kam, MD (1) · Jeffrey B Kopp, M.D. (1) · Madhav Menon, MD (1) · Marcelo Marcos Morales, MD,PHD (1) · Nasser Aghdami, MD,PhD (1) · Pedro Chocair, Prof. PhD (1) · Rosangela Villar, MD (1) · Rozita Hosseini, MD (1) · Soroosh Shekarchian, MD (1)